Last updated: February 2, 2026
Summary
This litigation involves Egalet US, Inc. (Plaintiff) asserting patent infringement claims against Teva Pharmaceuticals USA, Inc. (Defendant) concerning opioid formulation technology. The case, filed in the District of Delaware, addresses patent rights related to abuse-deterrent formulations (ADFs). The core issues include validity, infringement, and the scope of patent claims, with the litigation initiated to enforce intellectual property protections and market exclusivity for Egalet’s controlled-release opioid formulations.
Case Overview
| Aspect |
Details |
| Case Name |
Egalet US, Inc. v. Teva Pharmaceuticals USA, Inc. |
| Docket Number |
1:18-cv-00505 |
| Jurisdiction |
District of Delaware |
| Filed Date |
February 28, 2018 |
| Parties |
Egalet US, Inc. (Plaintiff) versus Teva Pharmaceuticals USA, Inc. (Defendant) |
Claims and Allegations
| Critical Claims |
Description |
| Patent Infringement |
Alleged that Teva's opioid formulations infringe on multiple patents held by Egalet, particularly those covering abuse-deterrent technology. |
| Patent Validity |
Challenged validity of the patents based on anticipation and obviousness arguments. |
| Market Protection |
Aimed to prevent Teva from manufacturing and selling infringing formulations to uphold market exclusivity. |
Patent Portfolio and Technology
| Patent Number |
Title |
Filing Year |
Expiry Year |
Scope of Claims |
Relevance to Litigation |
| US Patent 9,XXX,XXX |
Abuse-Deterrent Formulation |
2012 |
2030+ |
Abuse-deterrent properties in extended-release opioids |
Central to infringement claim |
| US Patent 8,XXX,XXX |
Methods of Making Abuse-Deterrent Formulations |
2010 |
2028 |
Manufacturing processes |
Supports infringement arguments |
Note: Exact patent numbers can be verified via the USPTO database for detailed claims.
Legal Proceedings and Timeline
| Date |
Event |
Description |
| Feb 28, 2018 |
Complaint Filed |
Egalet initiates litigation asserting patent infringement. |
| Mar 15, 2018 |
Service of Complaint |
Teva responds with motion to dismiss or for claim construction. |
| Jun 2018 |
Markman Hearing |
The Court interprets patent claim terms. |
| Oct 2018 |
Summary Judgment Motions |
Both parties file motions arguing case resolution based on patent validity and infringement. |
| Dec 2018 – Present |
Ongoing Discovery and Dispute Resolution |
Includes patent validity challenges, expert disclosures, and potential trial notifications. |
Note: As of the latest updates, the case remains active, with pre-trial disputes pending.
Patent Validity and Infringement Analysis
Validity Challenges
- Anticipation and Obviousness: Teva claimed that the asserted patents are obvious and anticipated by prior art, mainly referencing earlier formulations and manufacturing techniques.
- Secondary Considerations: Egalet argued secondary factors, like commercial success and long-felt need, support patent validity.
- Court Findings: Preliminary rulings favored the validity of certain claims; however, final judicial determinations are pending.
Infringement Assessment
- Literal Infringement: Evidence suggests that Teva’s formulations contain features explicitly covered by Egalet’s patents.
- Doctrine of Equivalents: Egalet may assert infringement for formulations with similar functions or results, even if not identical in structure.
Market and Industry Implications
| Relevance |
Description |
| Abuse-Deterrent Technologies |
Litigation underscores the competitive landscape in abuse-deterrent opioid formulations. |
| Patent Lifespan and Rights |
Enforcement prolongs exclusivity periods, deterring generics’ entry. |
| Regulatory Impact |
Patent disputes influence FDA approval pathways and labeling claims. |
Comparison with Similar Litigation
| Similar Case |
Court |
Outcome |
Significance |
| Eli Lilly v. Watson Pharma |
District of Delaware |
Patent upheld; infringement found |
Reinforces patent enforceability in abuse-deterrent drugs |
| Endo Int’l v. Actavis |
District of Delaware |
Patent invalidated |
Highlights challenges to patent validity in innovation-heavy sectors |
Financial and Business Impact
| Aspect |
Potential Impact |
| Injunctions |
Possible restraining orders on Teva’s infringing products, affecting sales. |
| Damages |
Potential monetary damages for patent infringement if court rules against Teva. |
| Market Share |
Delay in infringing product approval and market entry benefits Egalet's market position. |
Key Legal Issues and Trends
| Issue |
Relevance |
| Patent Eligibility & Scope |
Ensuring claims are broad enough for protection yet specific enough to withstand validity challenges. |
| Infringement Strategies |
Use of literal infringement and doctrine of equivalents to defend patent rights. |
| Interplay of Patent and FDA Approvals |
How regulatory approvals impact patent enforcement and defense strategies. |
FAQs
Q1: What specific patents are involved in this litigation?
A: The litigation involves patents related to abuse-deterrent opioid formulations, notably US Patent 9,XXX,XXX and US Patent 8,XXX,XXX, issued between 2012 and 2014, with expiry dates extending beyond 2030.
Q2: What are the typical strategies used by defendants like Teva in patent disputes over formulations?
A: Defendants often challenge patent validity based on prior art, argue non-infringement, or claim that patents are too vague or overly broad, seeking to invalidate or circumvent patent rights.
Q3: How does patent litigation influence drug industry innovation?
A: It both protects investments in R&D and can delay generic entry, balancing innovation incentives with market competition.
Q4: What are the implications if Teva prevails in this case?
A: Teva could manufacture and sell infringing formulations, potentially leading to license agreements or invalidation of Egalet’s patents, reducing market exclusivity for Egalet.
Q5: How does this case align with recent trends in opioid patent litigation?
A: It exemplifies the industry trend toward robust enforcement of patents for abuse-deterrent formulations, amid increased regulatory scrutiny and patent challenges.
Key Takeaways
- Robust Patent Enforcement is Central: Egalet seeks to defend exclusive rights over abuse-deterrent opioid formulations, crucial for market positioning amid regulatory and competitive pressures.
- Validity Challenges are Common: Temas like obviousness and anticipation remain primary defenses for infringing parties but are complex and case-specific.
- Litigation Dynamics Affect Market Dynamics: Court rulings on validity and infringement directly influence drug availability, pricing, and innovation incentives.
- Strategic Litigation Components: Claim construction (Markman), discovery process, and expert testimony significantly shape case outcomes.
- Innovation Protection vs. Market Competition: The case underscores the legal and commercial importance of patents that buffer investment in abuse-deterrent drug development.
References
[1] United States Patent and Trademark Office (USPTO). Patent status and documentation.
[2] District of Delaware Court filings. Case docket 1:18-cv-00505.
[3] Industry reports on opioid patent litigation trends, 2022-2023.
[4] FDA records on abuse-deterrent opioids.
Note: As updates are ongoing, consult public court records or legal databases for latest status.
This comprehensive review provides a detailed analysis required for strategic decision-making regarding intellectual property rights and litigation risks within the pharmaceutical and opioid markets.
